Colorectal Cancer Clinical Trial
Official title:
Effects of Different Fasting Strategies in Perioperative Period on Postoperative Recovery, Immune Function, and Long-term Prognosis in Patients With Radical Resection of Colorectal Cancer
In 2018, colorectal cancer is the third most common malignant tumor in terms of morbidity and second mortality in the world. Surgical resection is still the main treatment for colorectal cancer.With the introduction of the ERAS, the latest international and domestic guidelines for fasting before surgery all advocate shortening the fasting time. For example, 2 hours before surgery, oral take cleared fluids, including water, sugar water, fruit juice, tea and black coffee (without milk) is allowed.Solid food can be consumed 4 hours before surgery, and oral diet should be resumed as soon as possible after surgery. Changes in diet, nutritional status, and physical activity are closely related to the incidence of colorectal cancer. Therefore, we believe that the intestine may be very sensitive to different fasting times during the perioperative period. Prolonging the fasting time may improve the prognosis by improving postoperative insulin resistance, reducing inflammation and protecting anti-tumor immune function in patients with colorectal cancer.Prolonged fasting time seems to be contrary to the results of some studies, and whether it is applicable to patients with tumor surgery is unclear. Therefore, there is an urgent need to conduct large-scale, prospective, randomized controlled clinical studies to clarify the most suitable perioperative fasting strategy (including composition, interval, and amount) for cancer patients, which can not only reduce surgical stress and speed up postoperative rehabilitation,reduce postoperative metastasis and recurrence and improve mid- and long-term prognosis.
As early as a century ago, Investigators proved that diet restriction can prevent the
occurrence of transplanted tumors in mice. Following this milestone, many animal studies
(from mice to primates) have confirmed that diet restriction can slow the development of
spontaneous tumors and transplanted tumors. A study of macaque monkeys for more than 20 years
revealed that restricting diet by 30% can reduce the incidence of tumors by 50%, which makes
people see the potential value of restricting diet to humans. However, whether diet
restriction can also reduce the incidence of human tumors is not entirely clear. The growth
of tumor cells requires a nutrient-rich environment, and the lack of glucose and amino acids
caused by diet restrictions is very detrimental to tumor cells. Unlike normal cells, tumor
cells mainly rely on glycolysis (Warburg effect) rather than energy and biosynthetic
precursors provided by oxidative phosphorylation for proliferation. These characteristics
make tumor cells extremely sensitive to changes in the surrounding environment, which is
called differential stress sensitization (DSS).Investigators found that the use of low sugar
and low serum in a cell model to simulate periodic fasting can enhance the sensitivity of
human or animal tumor cells to doxorubicin and cyclophosphamide, and also found that they
were transplanted subcutaneously in mice Melanoma or breast cancer, diet combined with
chemotherapy is better than chemotherapy alone; in the mouse metastatic neuroblastoma model,
fasting before high-dose chemotherapy can successfully reduce the toxic side effects of
chemotherapy drugs and reduce metastasis and prolong the tumor-free survival. Surgery and
stress are twin brothers. Surgical resection, blood flow blockage, ischemia-reperfusion
injury, tissue damage, local inflammatory factor release, and changes in systemic
neuroendocrine and metabolism all affect blood flow, blood coagulation, and immune function.
Investgators found restricted diet can reduce the inflammatory response after myocardial
ischemia-reperfusion injury in mice. Many animal experiments have confirmed that
perioperative fasting can effectively protect the liver, kidneys, and brain from organ
damage. The specific mechanism may be related to fasting increasing antioxidant enzyme
activity, reducing insulin-like growth factor-1 (IGF-1), and activating the autophagy
pathway. Similar to chemotherapy, there is currently no randomized clinical controlled study
to evaluate the impact of individualized perioperative dietary regimens (such as restricted
diet) on the prognosis of tumor surgery.
In 2018, colorectal cancer is the third most common malignant tumor in terms of morbidity and
second mortality in the world. Surgical resection is still the main treatment for colorectal
cancer.With the introduction of the ERAS, the latest international and domestic guidelines
for fasting before surgery all advocate shortening the fasting time. For example, 2 hours
before surgery, oral take cleared fluids, including water, sugar water, fruit juice, tea and
black coffee (without milk) is allowed.Solid food can be consumed 6 hours before surgery, and
oral diet should be resumed as soon as possible after surgery. Changes in diet, nutritional
status, and physical activity are closely related to the incidence of colorectal cancer.
Therefore, we believe that the intestine may be very sensitive to different fasting times
during the perioperative period. Prolonging the fasting time may improve the prognosis by
improving postoperative insulin resistance, reducing inflammation and protecting anti-tumor
immune function in patients with colorectal cancer.Prolonged fasting time seems to be
contrary to the results of some studies, and whether it is applicable to patients with tumor
surgery is unclear. Therefore, there is an urgent need to conduct large-scale, prospective,
randomized controlled clinical studies to clarify the most suitable perioperative fasting
strategy (including composition, interval, and amount) for cancer patients, which can not
only reduce surgical stress and speed up postoperative rehabilitation,reduce postoperative
metastasis and recurrence and improve mid- and long-term prognosis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |